Who Should Not Take GLP-1 Medications (Wegovy, Ozempic, Zepbound)?

Hard Contraindications: Who Must Not Use GLP-1 Agents

The Wegovy prescribing label lists two absolute contraindications: a personal or family history of medullary thyroid carcinoma (MTC) and Multiple Endocrine Neoplasia syndrome type 2 (MEN2). [1] Both semaglutide and tirzepatide caused dose-dependent thyroid C-cell tumors in rodent studies, and while human incidence has not been confirmed in trials, the FDA considers the theoretical risk sufficient to warrant a hard stop. [1, 2] Pregnancy is a third absolute contraindication discussed further below.

Rodent data are not automatically predictive of human outcomes, but thyroid C-cell expression of the GLP-1 receptor differs between species. The FDA's position, reflected in the black-box warning on every approved GLP-1 label, is that no safe human threshold has been established. [1] Because MTC carries a 10-year survival rate below 30% in metastatic disease, clinicians are instructed to ask specifically about personal and family thyroid cancer history at every new-patient visit. [3] Anyone with a confirmed RET proto-oncogene mutation should not take these drugs regardless of their own cancer history.

The Zepbound (tirzepatide) label carries an identical thyroid C-cell warning. [2] Patients who have already been diagnosed with MTC or who are undergoing evaluation for a suspicious thyroid nodule must defer GLP-1 therapy until the workup is complete.

Pregnancy and GLP-1 Medications

GLP-1 receptor agonists should not be used during pregnancy. Animal studies with semaglutide showed reduced fetal weight, skeletal abnormalities, and fetal death at doses producing exposures overlapping therapeutic human plasma levels. [1] The Wegovy label specifies that semaglutide should be discontinued at least 2 months before a planned pregnancy because of the drug's long elimination half-life of approximately 7 days. [1]

The American Society for Reproductive Medicine notes that obesity itself impairs fertility and that GLP-1 agents are sometimes used before assisted reproductive technology cycles to improve outcomes. [4] Once pregnancy is confirmed, however, the medication must be stopped. No adequate human data exist on semaglutide or tirzepatide embryotoxicity, and the FDA categorizes both as contraindicated in pregnancy. [1, 2]

Women of reproductive age should use effective contraception while on any GLP-1 agent. Oral contraceptive absorption may be affected because GLP-1 drugs slow gastric emptying, a concern specifically flagged in the Rybelsus (oral semaglutide) label. [5] A barrier method or non-oral contraceptive should be discussed with the prescribing clinician.

Breastfeeding data are equally limited. Semaglutide is detectable in rat milk, and because GLP-1 receptor expression exists in neonatal gut tissue, the FDA recommends that patients either stop the drug or refrain from breastfeeding. [1]

Pancreatitis History

Acute pancreatitis has been reported in patients taking GLP-1 receptor agonists, and the FDA requires a warning in all GLP-1 prescribing information. [1, 2] The absolute risk remains low. In the LEADER trial (liraglutide, N=9,340), pancreatitis rates were 0.4% in the liraglutide group vs. 0.3% placebo, a non-statistically significant difference. [6] STEP-1 (semaglutide 2.4 mg, N=1,961) saw pancreatitis in 0.2% of the semaglutide group. [7]

A single episode of alcohol-induced or gallstone pancreatitis does not automatically bar GLP-1 use. Idiopathic recurrent pancreatitis or confirmed autoimmune pancreatitis is a different matter. The American Association of Clinical Endocrinology's obesity guidelines state that GLP-1 agents should be used "with caution" in patients with a history of acute pancreatitis and are "not recommended" in those with a history of chronic pancreatitis. [8] Prescribers should document the discussion and monitor serum lipase if symptoms emerge.

If a patient develops persistent severe abdominal pain radiating to the back while on a GLP-1 drug, the medication should be stopped and pancreatitis ruled out before resuming. [1]

Gallbladder Disease

GLP-1 agents increase the risk of cholelithiasis (gallstones) and cholecystitis. In STEP-1, cholelithiasis occurred in 2.6% of the semaglutide group vs. 1.2% placebo (P<0.001). [7] Rapid weight loss independently promotes gallstone formation by altering bile cholesterol saturation, and GLP-1 drugs may reduce gallbladder motility as a secondary mechanism. [9]

Patients with prior cholecystitis or known gallstones are not absolutely contraindicated from GLP-1 therapy, but the prescribing clinician should weigh the added risk. Patients who develop biliary colic symptoms, jaundice, or fever on a GLP-1 agent need prompt hepatobiliary imaging. [1]

Diabetic Retinopathy

In STEP-2 (semaglutide 1.0 mg in type 2 diabetes, N=1,210), diabetic retinopathy complications occurred in 6.3% of the semaglutide group vs. 4.2% placebo, a pattern consistent with the "early worsening" phenomenon observed when glucose levels fall rapidly. [10] The same signal appeared in the SUSTAIN-6 cardiovascular outcomes trial. [11]

The FDA label recommends monitoring patients with a history of diabetic retinopathy for progression. [1] This is not an absolute contraindication. Patients with pre-proliferative or proliferative retinopathy should have an ophthalmology evaluation before starting a GLP-1 agent, and glycemic targets should be adjusted to avoid precipitous HbA1c drops in the first 3 months. An HbA1c reduction of more than 2 percentage points over 3 months correlates with the highest retinopathy worsening risk. [11]

Severe Gastrointestinal Disease

GLP-1 receptor agonists slow gastric emptying significantly. In patients with established gastroparesis, this pharmacodynamic effect can precipitate severe nausea, vomiting, aspiration, and dangerous dehydration. The Wegovy label lists "pre-existing severe gastrointestinal disease" as a reason to avoid the drug. [1]

Inflammatory bowel disease in flare, bowel obstruction history, and gastric outlet obstruction are additional clinical scenarios where GLP-1 initiation should be deferred. [1] Published case series have described bezoar formation in patients with delayed gastric emptying who started semaglutide, underscoring the need for GI history review before prescribing. [12]

Patients with well-controlled IBD in remission are not categorically excluded, but the decision requires documented shared decision-making with both the prescribing clinician and a gastroenterologist.

Heart Rate and Cardiac Considerations

GLP-1 agents raise resting heart rate by 2 to 4 beats per minute on average. [7] For most people this is clinically trivial, but in patients with tachyarrhythmias, including inappropriate sinus tachycardia or paroxysmal supraventricular tachycardia, the additional rate burden may worsen symptoms. Formal cardiac contraindication data are limited, and the SELECT trial (semaglutide 2.4 mg in N=17,604 adults with obesity and established cardiovascular disease) actually showed a 20% reduction in major adverse cardiovascular events versus placebo (HR 0.80; 95% CI 0.72-0.90). [13] So the cardiovascular concern for most patients tips strongly in favor of GLP-1 use, not against it.

Patients with New York Heart Association Class IV heart failure have been excluded from GLP-1 trials. Prescribing in that population should involve cardiology input. [1]

Can You Drink Alcohol While Taking Semaglutide?

Moderate alcohol use is not a hard contraindication, but several overlapping mechanisms make the combination worth discussing with your prescriber. GLP-1 drugs slow gastric emptying, which alters alcohol absorption kinetics and may prolong intoxication at a given dose. [1] Both alcohol and GLP-1 agents affect blood glucose in opposite directions depending on timing: alcohol suppresses hepatic gluconeogenesis while GLP-1 drugs augment insulin secretion, so the combination can produce hypoglycemia, particularly in patients also taking sulfonylureas or insulin. [14]

Nausea is the most common early side effect of semaglutide, reported in 44% of patients in STEP-1 at some point during the 68-week trial. [7] Alcohol reliably worsens nausea, so even one drink during the dose-escalation phase may significantly impair tolerability.

A specific liver-related caution applies. Semaglutide received FDA approval in March 2024 for metabolic dysfunction-associated steatohepatitis (MASH) at a 2.4 mg weekly dose. [15] Alcohol is directly hepatotoxic and counteracts the anti-steatotic benefit. Patients taking semaglutide for MASH should treat alcohol as contraindicated, not merely a caution.

The practical guidance from the Wegovy prescribing information is that heavy alcohol use should be avoided. [1] The CDC defines heavy drinking as more than 14 drinks per week for men and more than 7 per week for women. [16] Staying below these thresholds does not eliminate risk; it only reduces it.

Ibuprofen and NSAIDs With Semaglutide

No pharmacokinetic drug-drug interaction study between ibuprofen and semaglutide has been published as a dedicated trial. The clinical concern is physiological rather than metabolic. Both NSAIDs and GLP-1 agents can reduce renal perfusion under certain conditions: NSAIDs by inhibiting prostaglandin-dependent afferent arteriolar dilation, and GLP-1 agents by promoting natriuresis and mild volume contraction during the early weight-loss phase. [17] The combination may increase acute kidney injury risk, particularly in older patients, those with baseline chronic kidney disease (eGFR <60 mL/min/1.73 m²), and those who are dehydrated from GLP-1-related vomiting. [17]

The FDA label does not list NSAIDs as a formal contraindication for semaglutide. [1] The practical clinical instruction is to use the lowest effective NSAID dose for the shortest necessary duration, ensure adequate hydration, and consider acetaminophen as a first-line analgesic alternative. Patients on both semaglutide and chronic NSAID therapy should have periodic serum creatinine monitoring. [17]

Metformin, sulfonylureas, and insulin all require specific dose adjustments when a GLP-1 agent is added. The GLP-1 augments insulin secretion, so hypoglycemia risk with concurrent sulfonylurea is real and sulfonylurea dose typically needs reduction. [1, 8]

How Fast Does Wegovy Work? (Timeline for New Patients)

Appetite suppression may begin within 1 to 3 days of the first injection in some patients, because GLP-1 receptors in the hypothalamus respond quickly to receptor occupancy. Weight loss visible on a scale typically appears between weeks 4 and 12. [7]

STEP-1 provides the most rigorous timeline data. At 20 weeks, the semaglutide 2.4 mg group had lost a mean of 8.0% of body weight vs. 2.5% in the placebo group. By 68 weeks, mean weight loss was 14.9% vs. 2.4% (P<0.001). [7] STEP-5, which extended follow-up to 104 weeks in N=304 patients, showed continued weight loss through approximately week 60, followed by a plateau at a mean of 15.2% reduction from baseline. [18]

Tirzepatide (Zepbound) works faster in aggregate. In SURMOUNT-1 (N=2,539), the 15 mg tirzepatide group achieved 20.9% mean weight loss at 72 weeks. [19] The 5 mg group reached 15.0%. Meaningful weight loss (more than 5%) was visible in the 15 mg group by week 12 in the trial's stratified analysis. [19]

Blood sugar improvement in type 2 diabetes precedes weight loss. In STEP-2 (N=1,210), HbA1c dropped by 1.6 percentage points with semaglutide 2.4 mg and by 1.5 percentage points with semaglutide 1.0 mg at 68 weeks, with statistically significant separation from placebo by week 8. [10]

Dose escalation delays full efficacy. Wegovy starts at 0.25 mg weekly and reaches the 2.4 mg maintenance dose after 16 to 20 weeks of monthly dose increases. [1] Patients should not compare their week-8 results to trial endpoint results without accounting for this escalation schedule.

Who Can Take GLP-1 Agents: Approved Indications

FDA-approved indications set the baseline for who should be considered. Wegovy (semaglutide 2.4 mg) is approved for adults with a BMI of 30 or above, or BMI of 27 or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. [1] The approval was extended in December 2023 to include adolescents aged 12 and older meeting the same BMI thresholds. [1]

Ozempic (semaglutide 1.0 mg) is approved for glycemic control in type 2 diabetes and for cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease. [20] Zepbound (tirzepatide) mirrors the Wegovy adult obesity indications and additionally carries an approval for obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA data. [2]

The AACE 2016 obesity clinical practice guidelines, which remain the backbone of U.S. obesity pharmacotherapy guidance, state that pharmacotherapy is appropriate when lifestyle modification alone has not achieved a 5% weight reduction after 3 to 6 months of documented effort. [8] GLP-1 agents now sit at the top of the AACE preferred-agent list given their efficacy and cardiovascular safety data. [8]

Renal and Hepatic Impairment

Semaglutide is not renally cleared, and the Wegovy label states that no dose adjustment is required for chronic kidney disease of any stage. [1] This is an area where GLP-1 agents have an advantage over metformin, which is contraindicated below eGFR 30. Liraglutide (Saxenda, Victoza) has similar renal pharmacokinetics. [21]

Hepatic impairment data are limited. Mild to moderate hepatic impairment did not meaningfully alter semaglutide exposure in pharmacokinetic studies, and no dose adjustment is listed. [1] Severe hepatic impairment (Child-Pugh C) was excluded from key trials, so prescribing in that population should be done cautiously with close monitoring.

Thyroid Monitoring in Practice

Patients who begin a GLP-1 agent and develop a neck mass, dysphagia, hoarseness, or dyspnea should contact their clinician promptly and stop the medication pending workup. [1] These symptoms may indicate thyroid enlargement or, rarely, MTC. Routine calcitonin monitoring is not mandated by the FDA label but is endorsed by some endocrinologists for high-risk patients. The Endocrine Society's clinical practice guidance on GLP-1 use notes that the absolute human MTC risk signal remains unconfirmed in epidemiological data but that the rodent finding is "biologically plausible." [22]

Serum calcitonin baseline measurement before GLP-1 initiation is reasonable in patients with any thyroid nodule on imaging, a history of neck irradiation, or a first-degree relative with MTC. [22]